World Diabetes Day 2025: EMA Recommends First Treatment to Delay Type 1 Diabetes Onset
Date: 19 November 2025
World Diabetes Day 2025 has brought encouraging news for the type 1 diabetes community. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of teplizumab (Tzield) for patients with stage 2 type 1 diabetes.
This marks a significant milestone as the first-in-class treatment designed to delay the onset of stage 3 type 1 diabetes. The recommendation follows clinical evidence demonstrating teplizumab’s potential to postpone disease progression in at-risk individuals.
The CHMP’s positive opinion is an important step towards making this treatment available to patients across Europe. Final approval from the European Commission is now awaited.
Further Information:
